

**Limited Review Report on Unaudited Standalone Financial Results for the quarter ended June 30, 2025 of Indrayani Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**To the Board of Directors of Indrayani Biotech Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of Indowind Energy Limited ('the Company') for the quarter ended June 30, 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (the "Listing Regulations, 2015") as amended.
2. The Statement is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34, 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Ind AS and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**for Venkatesh & Co**

Chartered Accountants

FRN: 004636S



**CA Desikan G**

Partner

M No: 219101

UDIN: 25219101BMICNW9136

Chennai, 14<sup>th</sup> August 2025

**BLOCK 1, MODULE NO.33, 3rd FLOOR,SIDCO ELECTRONIC COMPLEX,  
THIRU VI KA INDUSTRIAL ESTATE,GUINDY CHENNAI - 600032**

## (₹ in INR 'Lakhs)

S.No	Particulars	3 months ended 30-June-2025	3 months ended 31-March-2025	3 months ended 30-June-2024	Year to date for period ended 30-June-2025	Year to date for period ended 30-June-2024	Previous year ended 31-March-2025
		Unaudited	Audited	Audited	Unaudited	Audited	Audited
1	<b>Income from Operations</b>						
	Net Sales/Revenue from Operations	668.57	928.31	1,079.09	668.57	1,079.09	3,776.91
2	Other Income	89.16	93.41	102.60	89.16	102.60	351.60
3	<b>Total Income (1+2)</b>	<b>757.73</b>	<b>1,021.72</b>	<b>1,181.69</b>	<b>757.73</b>	<b>1,181.69</b>	<b>4,128.51</b>
4	<b>Expenses</b>						
	(a) Cost of Materials consumed	335.28	279.66	484.52	335.28	484.52	1,478.43
	(b) Employee benefits expenses	150.15	330.35	403.58	150.15	403.58	1,323.68
	(c) Finance Costs	131.93	239.46	151.63	131.93	151.63	732.10
	(d) Depreciation and amortisation expense	15.25	6.41	31.98	15.25	31.98	102.49
	(e) Other expenses	108.09	145.60	92.93	108.09	92.93	427.18
5	<b>Total Expenditure excluding provisions and contingencies</b>	<b>740.70</b>	<b>1,001.48</b>	<b>1,164.64</b>	<b>740.70</b>	<b>1,164.64</b>	<b>4,063.88</b>
6	Operating Profit before Provisions and Contingencies (3-5)	17.03	20.24	17.05	17.03	17.05	64.63
7	Provisions (other than tax) and Contingencies	-	-	-	-	-	-
8	Exceptional Items	-	-	-	-	-	-
9	Profit (+)/ Loss (-) from Ordinary Activities before tax (6-7-8)	17.03	20.24	17.05	17.03	17.05	64.63
10	Tax expense	4.26	0	4.33	4.26	4.33	(80.00)
11	Net Profit(+)/ Loss(-) from Ordinary Activities after tax (9-10)	12.77	20.24	12.72	12.77	12.72	144.63
12	<b>Other Comprehensive Income</b>	-	-	-	-	-	-
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total Comprehensive income for the period attributable to</b>	-	-	-	-	-	-
	Comprehensive income for the period attributable to the owners of the Company	-	-	-	-	-	-
	<b>Total Comprehensive income for the period attributable to the non-controlling interest</b>	-	-	-	-	-	-
13	Paid-up equity share capital (Rs.10 being the Face Value per share)	4553.63	4553.63	4553.63	4553.63	4553.63	4553.63
14	Reserves excluding Revaluation Reserves (as per balance sheet of previous accounting year)	-	-	-	-	-	-
15	<b>Analytical Ratios</b>	-	-	-	-	-	-
(i)	Earnings Per Share (EPS)						
	- Basic	0.03	0.25	0.03	0.03	0.03	0.32
	- Diluted	0.03	0.25	0.03	0.03	0.03	0.32
16	<b>NPA Ratios</b>						
(a)	Gross/Net NPA	-	-	-	-	-	-
(b)	% of Gross/Net NPA	-	-	-	-	-	-
(c)	Return on Assets	-	-	-	-	-	-

1. The above standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 14th August 2025 and have been subjected to review by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

3. Previous period figures have been regrouped wherever necessary.

4. There is no investor complaint received during the Quarter

For Indrayani Biotech Limited

Swaminathan Govindarajan  
Whole-time Director  
DIN : 02481041

**Limited Review Report on Unaudited Consolidated Financial Results for the quarter ended June 30, 2025 of Indrayani Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**To the Board of Directors of Indrayani Biotech Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Indrayani Biotech Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the group') for the quarter ended June 30, 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (the "Listing Regulations, 2015") as amended.
2. The Statement is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34, 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

The Statement includes the results of the following entities:

S. No.	Name of the entity	Relationship
1	IBL Health Care Limited	Subsidiary
2	HSL Agri Solutions Limited	Subsidiary
3	HSL Prime Properties Private Limited	Subsidiary
4	Healthway India Private Limited	Step Down Subsidiary
5	Dindigul Farm Products Limited*	Subsidiary
6	Matrix Boilers Private Limited	Subsidiary
7	IBL Investments Limited	Subsidiary

S. No.	Name of the entity	Relationship
8	IBL Social Foundation	Subsidiary
9	Kniss Laboratories Private Limited	Step Down Subsidiary

**\*Consolidation Comprises of Financial results of Dindigul Farm Products Limited by the virtue of Control established over Board of Directors and decisions of management.**

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Ind AS and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the financial statement / financial information of 6 Subsidiaries and 3 step down subsidiaries included in the consolidated unaudited financial results, whose interim financial information for the Period ended 30th June, 2025 reflects total revenues of ₹ 2,344.81 Lakhs, total comprehensive profit / (loss) of ₹ 3.83 Lakhs for the period ended on that date as considered in the consolidated financial results.

**for Venkatesh & Co**

Chartered Accountants

FRN: 004636S




**CA Desikan G**

Partner

M No: 219101

UDIN: 25219101BMICNV6411

Chennai., 14<sup>th</sup> August 2025

INDRAYANI BIOTECH LIMITED CIN: L40100TN1992PLC129301 BLOCK 1, MODULE NO.33, 3rd FLOOR,SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY CHENNAI - 600032							
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE PERIOD ENDED 30 JUNE 2025							
(₹ in INR 'Lakhs)							
S.No	Particulars	3 months ended 30-June-2025	3 months ended 31-March-2025	3 months ended 30-June-2024	Year to date for period ended 30-June-2025	Year to date for period ended 30-June-2024	Previous year ended 31-March-2025
		Unaudited	Audited	Audited	Unaudited	Audited	Audited
1	<b>Income from Operations</b>						
	Net Sales/Revenue from Operations	2,910.37	5,056.93	3,152.78	2,910.37	3,152.78	13,022.84
2	Other Income	105.62	277.63	4.43	105.62	4.43	312.58
3	<b>Total Income (1+2)</b>	<b>3,060.99</b>	<b>5,334.56</b>	<b>3,157.21</b>	<b>3,060.99</b>	<b>3,157.21</b>	<b>13,335.43</b>
4	<b>Expenses</b>						
	(a) Cost of Materials consumed	2,075.82	4,018.29	1,758.33	2,075.82	1,758.33	8,277.21
	(b) Employee benefits expenses	269.23	619.10	571.95	269.23	571.95	2,046.78
	(c) Finance Costs	217.08	707.21	224.87	217.08	224.87	1,176.27
	(d) Depreciation and amortisation expense	85.82	(171.55)	82.74	85.82	82.74	336.81
	(e) Other expenses	347.17	993.43	424.85	347.17	424.85	2,072.70
5	<b>Total Expenditure excluding provisions and contingencies</b>	<b>3,040.12</b>	<b>6,166.48</b>	<b>3,062.74</b>	<b>3,040.12</b>	<b>3,062.74</b>	<b>13,909.78</b>
6	Operating Profit before Provisions and Contingencies (3-5)	20.87	(831.92)	94.47	20.87	94.47	(574.35)
7	Provisions (other than tax) and Contingencies	-	-	-	-	-	-
8	Exceptional Items	-	-	-	-	-	-
9	Profit (+)/ Loss (-) from Ordinary Activities before tax (6-7-8)	<b>20.87</b>	<b>(831.92)</b>	<b>94.47</b>	<b>20.87</b>	<b>94.47</b>	<b>(574.35)</b>
10	Tax expense	5.22	20.67	9.45	5.22	9.45	36.40
11	Net Profit(+)/ Loss(-) from Ordinary Activities after tax (9-10)	<b>15.65</b>	<b>(852.59)</b>	<b>85.02</b>	<b>15.65</b>	<b>85.02</b>	<b>(610.75)</b>
12	Other Comprehensive Income	-	-	-	-	-	-
	A (i) Items that will not be reclassified to profit or loss	-	-2.61	-	-	-	-2.61
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Comprehensive income for the period attributable to	-	(855.20)	85.01	-	85.01	(613.36)
	Comprehensive income for the period attributable to the owners of the Company	<b>15.00</b>	<b>-584.06</b>	<b>43.90</b>	<b>4.07</b>	<b>43.90</b>	<b>-158.27</b>
	Total Comprehensive income for the period attributable to the non-controlling interest	<b>5.86</b>	<b>-271.14</b>	<b>41.11</b>	<b>11.58</b>	<b>41.11</b>	<b>-455.09</b>
13	Paid-up equity share capital (Rs.10 being the Face Value per share)	4553.63	4553.63	4553.63	4553.63	4553.63	4553.63
14	Reserves excluding Revaluation Reserves (as per balance sheet of previous accounting year)	-	-	-	-	-	-
15	<b>Analytical Ratios</b>	-	-	-	-	-	-
(i)	Earnings Per Share (EPS)						
	- Basic	0.03	-1.42	0.10	0.03	0.10	-0.35
	- Diluted	0.03	-1.42	0.10	0.03	0.10	-0.35
16	<b>NPA Ratios</b>						
(a)	Gross/Net NPA	-	-	-	-	-	-
(b)	% of Gross/Net NPA	-	-	-	-	-	-
(c)	Return on Assets	-	-	-	-	-	-

**Notes:**

- The above consolidated financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 14th August 2025 and have been subjected to review by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website [www.indrayani.com](http://www.indrayani.com)
- Previous period figures have been regrouped wherever necessary.
- There is no investor complaint received during the Quarter

For Indrayani Biotech Limited

Swaminathan Govindarajan  
 Whole-time Director  
 DIN : 02481041